The annual Drug Price Forecast from Vizient®, Provista’s
contracting partner, points to an increase in spend for
pharmaceuticals between Jan. 1 and Dec. 31, 2019. The forecast
predicts pricing for next year and explains the critical issues poised
to affect the cost and use of pharmaceuticals.
Biosimilars are a newer class of drug that hold the potential to alter the healthcare landscape by offering lower prices than originator branded biologics. A biosimilar medicine is a biological medicine that’s almost an identical copy to a licensed biological medicine already in use. It’s been shown to not have any clinically meaningful differences from the original biological medicine in terms of quality, safety and efficacy. So why aren’t more available?
The opioid crisis, now a public health emergency, is challenging non-acute providers to improve opioid stewardship and prescribing practices. At the same time, they must manage the dispensation of opioid alternatives such as high-cost analgesics, whose comparative effectiveness isn’t well understood. This forces providers into a balancing act.
The home infusion therapy market is growing rapidly and being influenced by new trends. At the same time, reimbursement and new therapies are creating challenges. To overcome obstacles, home infusion therapy providers must follow a proactive strategy that enables them to meet their profit margins while serving their patients’ needs.
Blake Gillum, the executive director for Infusion Solutions, has seen his company’s revenues and customer base double over the last five years. He needs a supply chain partner that can keep pace with his company’s rapid growth and new business offering of enteral feedings. In this case study, he explains how Provista offers the most aggressive contracts for the home infusion market, including Novaplus® private label injectables that deliver deep savings.
The Bipartisan Budget Act of 2018 which takes effect Jan. 1, 2019, will change how home infusion therapy providers are reimbursed by Medicare for supplies, drugs, and services associated with providing Part B home infusion drugs. This mitigates the effects of the 21st Century Cures Act by aligning reimbursement with the services home infusion pharmacies are currently providing.
The proper storage and handling of vaccines across the cold chain is essential to prevent spoilage and to keep patients protected from illnesses. Advice from the Centers for Disease Control and Prevention (CDC) and a pharmacist and director of Pharmacy Operations for Provista helps facilities safely manage their vaccines.